Core Insights - Climb Bio, Inc. has appointed Dr. Edgar D. Charles as Chief Medical Officer and Cindy J. Driscoll as Senior Vice President, Finance, enhancing its leadership team at a crucial time for the company [1][2] Leadership Appointments - Dr. Charles brings over 20 years of experience in immunology-focused pharmaceutical development, having previously held significant roles at Bristol Myers Squibb, where he led the development of various therapeutic candidates [2][3] - Cindy Driscoll has over two decades of experience in financial and administrative functions within the biopharma sector, previously serving as Senior Vice President of Finance at HC Bioscience [2][4] Clinical Development Focus - The company is focused on advancing its clinical studies for budoprutug and CLYM116, with Dr. Charles emphasizing the therapeutic potential of budoprutug in treating serious diseases where B cells are central to pathology [4][7] - Budoprutug is an anti-CD19 monoclonal antibody that has shown promise in B cell depletion, while CLYM116 is an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy [7] Inducement Equity Awards - Climb Bio has granted inducement equity awards to Dr. Charles and Ms. Driscoll, including stock options to purchase 600,000 and 200,000 shares of common stock, respectively, with an exercise price of $1.20 per share [5][6]
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer